EUVIMEDEUVIMED entdecken
Crossref

Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability

Yaoguang Huang, Lianyu Tang, Xiaoyu Shi, Wenwu Liu iD, Xupeng Yang, Mingyu Wang, Zifeng Guo, Wenjing Li, Xianduo Sun, Anhua Wang iD, Jingming Jia iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yaoguang Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 9, Protein Kinase Inhibitors. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CDK4 and CDK9 are key kinases governing cell cycle progression and transcriptional regulation, respectively. Accumulating evidence supports the therapeutic potential of their concurrent inhibition in oncology. Screening of our in-house natural product library identified kushenmin K, a flavonoid with modest CDK inhibitory and antiproliferative activities. A strategy combining scaffold hopping with structure-guided design yielded HS-36, a novel oxazolylflavone derivative, which potently inhibited both CDK4 (IC50 = 18.9 nM) and CDK9 (IC50 = 4.2 nM). This dual activity effectively blocked cell cycle progression and triggered apoptosis by downregulating key downstream effectors, translating into potent antiproliferative activity. Notably, it maintained this potent activity even in CDK4/6 inhibitor-resistant cell models. Furthermore, HS-36 possessed an excellent pharmacokinetic profile, including good oral bioavailability (F = 41.8%), which enabled solid and well-tolerated in vivo antitumor efficacy (TGI = 68.8%) in a MV-4-11 xenograft model. This work not only presents HS-36 as a promising lead compound but also validates our rational approach to optimizing natural product scaffolds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 9Protein Kinase InhibitorsDrug DesignFlavonesOxazolesHumansAnimalsBiological AvailabilityAdministration, OralCell Line, TumorStructure-Activity RelationshipMiceCell ProliferationApoptosisXenograft Model Antitumor AssaysMice, NudeDrug Screening Assays, Antitumor

Substanzen

Antineoplastic AgentsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 9Protein Kinase InhibitorsFlavonesCDK4 protein, humanCDK9 protein, humanOxazoles

Autor:innen und Institutionen

  • School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang 110016, People's Republic of China.
  • Department of Pharmacy, Peking University First Hospital, Beijing 100034, People's Republic of China.

ORCID-Profile: Wenwu Liu, Anhua Wang, Jingming Jia

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Huang, Y., Tang, L., Shi, X., Liu, W., Yang, X., Wang, M., Guo, Z., Li, W., Sun, X., Wang, A., & Jia, J. (2025). Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02206

Vancouver

Huang Y, Tang L, Shi X, Liu W, Yang X, Wang M, et al. Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02206

BibTeX
@article{Huang2025,
  author = {Huang, Yaoguang and Tang, Lianyu and Shi, Xiaoyu and Liu, Wenwu and Yang, Xupeng and Wang, Mingyu and Guo, Zifeng and Li, Wenjing and Sun, Xianduo and Wang, Anhua and Jia, Jingming},
  title = {Rational Design of Oxazolonylflavone Derivatives as Novel CDK4/9 Inhibitors with Potent Antitumor Efficacy and Oral Bioavailability},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02206}
}
Kostenlos starten →